The therapeutic HIV Env C5/gp41 vaccine candidate Vacc-C5 induces specific T cell regulation in a phase I/II clinical study

BACKGROUND: Levels of non-neutralising antibodies (AB) to the C5 domain of HIV Env gp120 are inversely related to progression of HIV infection. In this phase I/II clinical study we investigated safety of Vacc-C5, a peptide-based therapeutic vaccine candidate corresponding to C5/gp41(732–744) as well...

Descripción completa

Detalles Bibliográficos
Autores principales: Brekke, Kristin, Sommerfelt, Maja, Ökvist, Mats, Dyrhol-Riise, Anne Margarita, Kvale, Dag
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5366104/
https://www.ncbi.nlm.nih.gov/pubmed/28340570
http://dx.doi.org/10.1186/s12879-017-2316-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5366104/
https://www.ncbi.nlm.nih.gov/pubmed/28340570
http://dx.doi.org/10.1186/s12879-017-2316-x

Ejemplares similares